Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer

scientific article published on 17 November 2017

Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.2217/IMT-2017-0121
P698PubMed publication ID29145737

P2093author name stringMartin Reck
P2860cites workPD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison ProjectQ39135152
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialQ40163779
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trialQ40346982
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)Q42073978
Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung CancerQ42407789
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.Q48020812
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancerQ26471909
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?Q26741101
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapyQ26745516
Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumabQ27712488
First-line crizotinib versus chemotherapy in ALK-positive lung cancerQ27853101
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trialQ27853299
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trialQ27853360
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer AgentsQ28087754
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerQ28278736
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancerQ29620301
Pembrolizumab for the treatment of non-small-cell lung cancerQ29620851
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.Q30275719
Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?Q33296440
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trialQ37193792
Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapyQ37462524
The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis.Q38355766
The impact of clinical characteristics on outcomes from maintenance therapy in non-small cell lung cancer: A systematic review with meta-analysisQ38538741
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.Q38645064
Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States.Q38722972
Non-Small Cell Lung Cancer, PD-L1, and the PathologistQ38755369
Evaluation of dosing strategy for pembrolizumab for oncology indicationsQ38779793
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung CancerQ38975751
P433issue2
P921main subjectpembrolizumabQ13896859
P304page(s)93-105
P577publication date2017-11-17
P1433published inImmunotherapyQ18713038
P1476titlePembrolizumab as first-line therapy for metastatic non-small-cell lung cancer
P478volume10

Reverse relations

cites work (P2860)
Q55318335Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?
Q60922811Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle
Q93231440Combination of CHEK1/2 inhibition and ionizing radiation results in abscopal tumor response through increased micronuclei formation
Q57185180Critical appraisal of PD-L1 reflex diagnostic testing: current standards and future opportunities
Q93200655First-Line Systemic Treatments for Stage IV Non-Small Cell Lung Cancer in California: Patterns of Care and Outcomes in a Real-World Setting
Q92469117Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Q61445430Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15
Q64236602KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer
Q64091350PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions
Q92400317Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study
Q55398181Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy.
Q89666795Pleurodesis and Immunotherapy in NSCLC; Medical Thoracoscopy or VATS?
Q57299127Predictive pathology of lung cancer immunotherapy response
Q52663125Progress in the Management of Malignant Pleural Mesothelioma in 2017.
Q91831510Radioimmunoimaging of 125I-labeled anti-CD93 monoclonal antibodies in a xenograft model of non-small cell lung cancer
Q58089143Recovery of T-cell receptor V(D)J recombination reads from lower grade glioma exome files correlates with reduced survival and advanced cancer grade
Q103836615SKIL facilitates tumorigenesis and immune escape of NSCLC via upregulating TAZ/autophagy axis
Q90446250The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma
Q64882422Video-assisted thoracic surgery double sleeve resections: the next step.
Q91654615What is the potential use of platelet-rich-plasma (PRP) in cancer treatment? A mini review
Q92728812[Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer]